Fibroblast growth factor-1 therapy for advanced emphysema - A new tissue engineering approach for achieving lung volume reduction

Journal of Bronchology

Volumn 13, Issue 3, 2006, Pages 114-123

  Ingenito, Edward P ^a   Tsai, Larry W ^a   Suki, Elizabeth ^b   Hoffman, Andrew ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Aeris Therapeutics ^*  (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Emphysema; FGF 1; Fibroblast growth factors; Lung volume reduction; Tissue engineering

Indexed keywords

CHONDROITIN SULFATE; ELASTASE; FIBRIN; FIBROBLAST GROWTH FACTOR 1; SMOOTH MUSCLE ACTIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EMPHYSEMA; EPITHELIUM CELL; FEMALE; FEVER; HISTOPATHOLOGY; HYDROGEL; IMMUNOHISTOCHEMISTRY; LUNG VOLUME; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SCAR; SHEEP; TISSUE ENGINEERING; TOTAL LUNG CAPACITY;

EID: 33746341863     PISSN: 10708030     EISSN: 15367959     Source Type: Journal    
DOI: 10.1097/00128594-200607000-00004     Document Type: Article

References (24)

1. Toma TP, Hopkinson NS, Hillier J, et al. Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet. 2003;361:931-933.
2. Ingenito EP, Reilly JJ, Mentzer SJ, et al. Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. Am J Respir Crit Care Med. 2001;164:295-301.
3. Tsai L, Hoffman A, Berger RL, et al. Bronchoscopic lung volume reduction in a sheep model of heterogeneous emphysema. J Bronchol. 2004;11:83-86.
4. Fishman A, Martinez F, Naunhein K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059-2073.
5. Naunheim KS, Wood DE, Krasna MJ, et al. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg. 2006;131:43-53.
6. Ingenito EP, Berger RL, Henderson AC, et al. Bronchoscopic lung volume reduction using tissue engineering principles. Am J Respir Crit Care Med. 2003;167:771-778.
7. Washko GR, Kenny L, Pinto-Plata V, et al. Initial experience with a tissue engineering approach to bronchoscopic lung volume reduction in humans with emphysema. Chest. 2005;128(Suppl):496S.
8. Bartolak-Suki E, Tsai L, Hoffman A, et al. Transforming growth factor (TGF)-beta 1 is released and activated by trypsin during bronchoscopic lung volume reduction. Am J Respir and Critical Care Med. 2005;2:A207.
9. Deterding RR, Jacoby CR, Shannon JM. Acidic fibroblast growth factor and keratinocyte growth factor stimulate fetal rat pulmonary epithelial growth. Am J Physiol. 1996;271:L495-L505.
10. Gambarini AG, Miyamoto CA, Lima GA, et al. Mitogenic activity of acidic fibroblast growth factor is enhanced by highly sulfated oligosaccharides derived from heparin and heparan sulfate. Mol Cell Biochem. 1993;124:121-129.
11. Powell PP, Wang CC, Horinouchi H, et al. Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung. Am J Respir Cell Mol Biol. 1998;19:563-572.
12. Leslie CC, McCormick-Shannon K, Mason RJ. Heparin-binding growth factors stimulate DNA synthesis in rat alveolar type II cells. Am J Respir Cell Mol Biol. 1990;2:99-106.
13. Hughes SE, Hall PA. Immunolocalization of fibroblast growth factor receptor 1 and its ligands in human tissues. Lab Invest. 1993;69:173-182.
14. Grandaliano G, Di Paolo S, Monno R, et al. Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation. 2001;72:1437-1443.
15. Lindstedt KA, Wang Y, Shiota N, et al. Activation of paracrine TGF-betal signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. Faseb J. 2001; 15:1377-1388.
16. Chambers RC, Leoni P, Blanc-Brude OP, et al. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem. 2000;275:35584-35591.
17. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz). 2002;50:325-331.
18. Gailit J, Clarke C, Newman D, et al. Human fibroblasts bind directly to fibrinogen at RGD sites through integrin alpha(v)beta3. Exp Cell Res. 1997;232:118-126.
19. Rahman S, Aitken A, Flynn G, et al. Modulation of RGD sequence motifs regulates disintegrin recognition of alphaIIb beta3 and alpha5 beta1 integrin complexes. Replacement of elegantin alanine-50 with proline, N-terminal to the RGD sequence, diminishes recognition of the alpha5 beta1 complex with restoration induced by Mn2+ cation. Biochem J. 1998;335:247-257.
20. Voss B, Rauterberg J, Muller KM. The perivascular connective matrix. Pathol Res Pract. 1994;190:969-983.
21. Xue L, Tassiopoulos AK, Woloson SK, et al. Construction and biological characterization of an HB-GAM/FGF-1 chimera for vascular tissue engineering. J Vasc Surg. 2001;33:554-560.
22. Zakrzewska M, Krowarsch D, Wiedlocha A, et al. Highly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological action. J Mol Biol. 2005;352:860-875.
23. Detillieux KA, Cattini PA, Kardami E. Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. Can J Physiol Pharmacol. 2004;82:1044-1052.
24. Mueller SN, Thomas KA, Di Salvo J, et al. Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro. J Cell Physiol. 1989;140:439-448.